These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 26755435)

  • 1. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
    Bayliss R; Choi J; Fennell DA; Fry AM; Richards MW
    Cell Mol Life Sci; 2016 Mar; 73(6):1209-24. PubMed ID: 26755435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer.
    Hsu SC; Hung TH; Wang CW; Ng KF; Chen TC
    Pathol Int; 2015 May; 65(5):231-9. PubMed ID: 25708242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
    Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
    Thunnissen E; Bubendorf L; Dietel M; Elmberger G; Kerr K; Lopez-Rios F; Moch H; Olszewski W; Pauwels P; Penault-Llorca F; Rossi G
    Virchows Arch; 2012 Sep; 461(3):245-57. PubMed ID: 22825000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.
    Cheon SY; Kwon S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The EML4-ALK fusion gene in NSCLC and the clinical progress].
    Wu D; Yu H
    Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):435-40. PubMed ID: 21569650
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
    Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
    Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
    J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.
    Okamoto I; Nakagawa K
    Cancer Sci; 2012 Aug; 103(8):1391-6. PubMed ID: 22568572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors 
and Chemotherapy].
    Wang J; Xu X; Sun Y; Li H
    Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):372-376. PubMed ID: 34034462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.